Clinical Evidence
Prospective multi-center reader study demonstrates DeepGAD™ maintains diagnostic quality with 80% less gadolinium.
Key Findings
Non-Inferior Diagnostic Performance
Blinded neuroradiologist assessment (n=3) showed no significant difference in border delineation, internal morphology, or contrast enhancement between DeepGAD™ and full-dose images.
Improved Signal Characteristics
Higher SNR (32.4 vs 28.1, p<0.05) and vessel conspicuity compared to full-dose images.
Quantitative Metrics
86%
SSIM ±12.1
27 dB
PSNR ±3
101
Cases
3
Readers
Prospective multi-center study, 2024
Case Examples
Meningioma
Equivalent dural tail and enhancement pattern visualization
Metastasis
Improved perilesional edema conspicuity
AVM
Enhanced feeding vessel delineation